Lan Xie | COVID-19 Analysis | Research Excellence Award

Published on by Research Data Analysis

Assoc. Prof. Dr. Lan Xie | COVID-19 Analysis | Research Excellence Award

Tsinghua University | China

Assoc. Prof. Dr. Lan Xie is a leading researcher in drug discovery and traditional Chinese medicine (TCM) integration with modern biomedical technologies. She earned her M.D. in Clinical Medicine from Peking University and a Ph.D. in Biology from Tsinghua University. Dr. Xie completed postdoctoral training at Tsinghua University and a visiting scholar program at the University of Pittsburgh. She has held faculty positions at Tsinghua University since 2014, currently serving as Associate Professor at the School of Basic Medical Sciences. Her research focuses on combining TCM with systems biology, multi-omics, and artificial intelligence to develop novel therapeutic strategies. She pioneered the Molecular Materia Medica database and an intelligent TCM formulation algorithm leveraging gene expression profiles and dysregulated disease pathways. Her work has been recognized with numerous awards, including the Huaxia Medical Science and Technology Award, International Award for Contribution to Chinese Medicine, and multiple Tsinghua University teaching excellence awards. Dr. Xie’s research achievements encompass high-throughput TCM bioactive component screening, single-cell omics-based mechanistic studies, and pathway-guided intelligent drug formulation. With 1,716 citations by 47 documents, 47 publications, and an h-index of 24, her contributions continue to advance modern medicine by bridging traditional knowledge and cutting-edge technology.

Profile : Scopus

Featured Publications

“A universal gene expression signature-based strategy for the high-throughput discovery of anti-inflammatory drugs.” Inflammation Research. 2025.

“Identification of the fruit of Brucea javanica as an anti-liver fibrosis agent working via SMAD2/SMAD3 and JAK1/STAT3 signaling pathways.” Journal of Pharmaceutical Analysis. 2025.

“Pulsatilla chinensis functions as a novel antihyperlipidemic agent by upregulating LDLR in an ERK-dependent manner.” Chinese Medicine United Kingdom. 2024.

“Mechanism study of Xiaoyao San against nonalcoholic steatohepatitis-related liver fibrosis based on a combined strategy of transcriptome analysis and network pharmacology.” Pharmaceuticals. 2024.

Hongming Lv | Agricultural Data Analysis | Best Researcher Award

Published on by Research Data Analysis

Prof. Hongming Lv | Agricultural Data Analysis | Best Researcher Award

Heilongjiang Bayi Agricultural University | China

Prof. Hongming Lv holds a BVSc (2013) and MVetSc (2016) from Heilongjiang Bayi Agricultural University, followed by a PhD (2019) from Jilin University, College of Veterinary Medicine. He currently serves as Professor and Master’s supervisor, and is Director of the Department of Basic Veterinary Medicine at the College of Animal Science and Technology, Heilongjiang Bayi Agricultural University. A provincial “E-level” high-talent, he chairs the Veterinary Pharmacology & Toxicology Branch of the Chinese Association of Animal Science and Veterinary Medicine, and reviews for journals such as Food Function and Phytomedicine. His research focuses on phytochemicals in poultry and livestock stress regulation, the pathogenic mechanisms of mycotoxins in farm animals, and strategies for prevention and control. As first or corresponding author, he has published over 20 SCI-indexed papers—including ten in top-tier journals (one with a single-paper impact factor of 10.7) such as Redox Biology, Journal of Agricultural and Food Chemistry and Poultry Science. His work has been recognised by inclusion in the Stanford-compiled “Top 2% of Scientists” list for 2023 and 2024, election as Outstanding Youth of Heilongjiang Province (2021), a second-class prize in the Jilin Province Natural Science and Technology Award, and a first prize in University Education Teaching Achievement. With a current h-index of approximately 25 and total citations around 2,644, he is a rising figure in veterinary pharmacology and toxicology. Prof. Lv continues to advance understanding of oxidative-stress responses, Nrf2/ferroptosis signalling in animal health, and the application of natural compounds for mycotoxin mitigation.

Profile : Scopus

Featured Publications

Lv, H., Liu, J., He, Y., Xia, S., Qiao, C., & Xu, C. (2024). “The ameliorative role of Licochalcone A on Aflatoxin B₁-triggered hepatotoxicity partially by activating Nrf2 signaling pathway.” Journal of Agricultural and Food Chemistry.

Liu, J., Zheng, Y., Yang, S., Zhang, L., Liu, B., Zhang, J., Yu, X., Wei, X., Li, S., Wang, J., & Lv, H. (2024).* “Targeting antioxidant factor Nrf2 by raffinose ameliorates lipid-dysmetabolism-induced pyroptosis, inflammation and fibrosis in NAFLD.” Phytomedicine.

Xia, S., He, Y., Yang, S., Zhang, L., Yu, X., Zhen, L., Wang, C., & Lv, H. (2024).* “Licochalcone A mitigates aflatoxin B₁-induced immunotoxicity via ferroptosis in the bursa of broilers and macrophages.” Poultry Science.

Liu, J., Wu, J., Qiao, C., He, Y., Xia, S., Zheng, Y., & Lv, H. (2023).* “Impact of chronic cold exposure on lung inflammation, pyroptosis and oxidative stress in mice.” International Immunopharmacology.

Lv, H., An, B., Yu, Q., Cao, Y., Liu, Y., & Li, S. (2020). “The hepatoprotective effect of myricetin against lipopolysaccharide and D-galactosamine-induced fulminant hepatitis.” International Journal of Biological Macromolecules.

Yuanxuan Cai | Healthcare Data Analysis | Best Researcher Award

Published on by Research Data Analysis

Ms. Yuanxuan Cai | Healthcare Data Analysis | Best Researcher Award

Ms. Yuanxuan Cai | Healthcare Data Analysis Huazhong University of Science and Technology | China

Ms. Yuanxuan Cai is a dedicated doctoral candidate in Pharmacy at Huazhong University of Science and Technology, with a strong academic background in pharmacoepidemiology and drug safety. Her research focuses on adverse drug event (ADE) risk assessment, pediatric pharmacovigilance, and neural network-based drug safety models. Yuanxuan has co-authored several peer-reviewed publications and contributed to multiple national and provincial research projects. She is highly skilled in data analysis, coding, and drug safety evaluation. With a passion for mental health and healthcare policy, she aims to improve public health outcomes through data-driven decision-making in clinical pharmacology and post-marketing drug surveillance.

Professional Profile

SCOPUS

Education 

Yuanxuan Cai is currently pursuing her Ph.D. in Pharmacy at Huazhong University of Science and Technology, Her coursework includes health policy, hospital management, and metrology analysis. She earned her Bachelor of Science in Pharmacy from the same university completing courses in medical statistics, pharmacology, and pharmaceutics. Throughout her academic journey, she has consistently demonstrated excellence in both theoretical and applied pharmaceutical sciences, receiving multiple scholarships and recognitions. Her educational background equips her with a strong foundation for advanced research in clinical drug safety and public health policy.

Professional Experience 

Ms. Cai has extensive experience participating in multiple high-impact research projects supported by the National Natural Science Foundation of China (NSFC) and provincial programs. Her work includes designing project frameworks, managing large-scale ADE data, performing signal detection using Python and SQL, and applying neural network models to evaluate drug safety. She has played key roles in studies on pediatric medications, oxaliplatin toxicity, and cephalosporin use in children. Yuanxuan is proficient in real-world data analysis, database management, and pharmacovigilance system development. Her hands-on experience with interdisciplinary teams reflects a commitment to improving healthcare safety through evidence-based approaches.

Awards and Recognition 

Yuanxuan Cai has received numerous accolades for her academic excellence and research contributions. These include the prestigious National Postgraduate Scholarship (2021), a continuous Postgraduate Academic Scholarship (2020–2024), and the Merit Student Award (2021). She also secured the 3rd Prize in the “Outstanding Knowledge and Action” competition and the 2nd Prize in the Qiaokou Innovation Scholarship (2022). As an undergraduate, she was honored with the Science and Technology Innovation Scholarship twice and was named an Outstanding Graduate in 2022. These recognitions highlight her commitment to academic rigor, innovation, and impactful research in pharmaceutical sciences.

Research Skills 

Yuanxuan Cai is proficient in advanced research methodologies, particularly in pharmacoepidemiology and big data analysis. She has hands-on experience with data cleaning and signal detection in ADE databases using Python and SQL. Her skill set includes constructing neural network models and applying logistic regression for predictive drug safety assessments. She has effectively used social network analysis and the Delphi method in pharmacovigilance research. Her coding proficiency extends to R for statistical analysis. Yuanxuan’s interdisciplinary expertise enables her to manage large datasets, evaluate drug combinations, and contribute meaningfully to clinical safety decision-making and public health improvement.

Publications

Suspected Adverse Drug Reactions Related to Statins: Analysis of Spontaneous Reports in Hubei Province, China (2014–2022)

  • Authors: Wang H, Bi H, Shangguan X, Chen Z, Huang R, Chen X, Cai Y*

  • Journal: Expert Opinion on Drug Safety

  • Year: 2025 (Accepted)

Predictive Model of Oxaliplatin-induced Liver Injury Based on Artificial Neural Network and Logistic Regression

  • Authors: Huang R, Cai Y, He Y, Yu Z, Zhao L, Wang T, et al.

  • Journal: Journal of Clinical and Translational Hepatology

  • Year: 2023

Risk Factors for Oxaliplatin-induced Hypersensitivity Reaction in Patients with Colorectal Cancer

  • Authors: Song Q, Cai Y, Guo K, Li M, Yu Z, Tai Q, et al.

  • Journal: American Journal of Translational Research

  • Year: 2022

Status and Safety Signals of Cephalosporins in Children: A Spontaneous Reporting Database Study

  • Authors: Cai Y, Yang L, Shangguan X, Zhao Y, Huang R

  • Journal: Frontiers in Pharmacology

  • Year: 2021

Safety of Traditional Chinese Medicine Injection Based on Spontaneous Reporting System from 2014 to 2019 in Hubei Province, China

  • Authors: Huang R, Cai Y, Yang L, Shangguan X, Ghose B, Tang S

  • Journal: Scientific Reports

  • Year: 2021